Navigation Links
BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
Date:9/8/2009

HERNDON, Va., Sept. 8 /PRNewswire/ -- BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

BHR will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), closed-head trauma TBI at 100-120 medical centers in the United States, Europe, Israel and additional countries.

Randomized patients will receive a five-day (120-hour) intravenous infusion of progesterone or placebo. Unlike intravenous progesterone infusions described in the medical literature, BHR-100 is a ready-to-use infusion designed to meet all U.S. Food and Drug Administration approval requirements.

BHR is collaborating with the American Brain Injury Consortium (ABIC) and the European Brain Injury Consortium (EBIC) to identify the trial sites and help design the clinical study. PRA International is the Contract Research Organization for the trial.

TBI is a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to permanent or temporary impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

Approximately 1.5 million Americans per year suffer a traumatic brain injury, resulting in 50,000 deaths, 235,000 hospitalizations and 80,000 cases of long-term disability. Incidence of TBI in all industrialized countries is comparable to that in the U.S., with estimates ranging from 150 to more than 300 per 100,000. There are approximately 66,000 deaths annually attributed to TBI in Europe.

The leading cause of TBI in the world is road traffic accidents, accounting for 40-50 percent of the hospitalizations for TBI.

There are currently no approved medications to improve outcomes following TBI.

The SyNAPSe study will build on promising results achieved in several previous clinical trials that demonstrated a mortality benefit and improved functional outcomes in TBI patients treated with progesterone. BHR has exclusively licensed the rights to a patent family claiming the use of progesterone to treat traumatic brain injury, along with preclinical and clinical data from a Phase 2 TBI study.

About BHR

Founded in January 2008, BHR Pharma, LLC (www.bhr-pharma.com) is a pharmaceutical research and development (R&D) company located near Washington, DC. BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs.

A wholly owned subsidiary of Besins Healthcare SA (www.besins-healthcare.com), which markets healthcare products in 93 countries, BHR manages all of Besins' global R&D activities. Those activities primarily leverage proprietary parenteral drug formulations, including the Enhanced Hydroalcoholic Gel (EHG((R))) technology pioneered and commercially launched by Besins in 1975.


'/>"/>
SOURCE BHR Pharma, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
4. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
5. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
6. Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
10. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
11. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 Transparency ... which provides an exhaustive study of the U.S. substance ... 242 companies are functional in this market at ... the leading companies, such as GlaxoSmithKline Plc., Pfizer ... aggressively on various marketing strategies to increase their ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
Breaking Medicine News(10 mins):